Non-users | Users | |||||||
---|---|---|---|---|---|---|---|---|
Patients | Deaths | Person-years | Patients | Deaths | Person-years | Unadjusted HR (95% CI) | Adjusteda HR (95% CI) | |
All patientsb | ||||||||
Main analysis | 2005 | 1268 | 4558 | 372 | 199 | 612 | 1.38 (1.19, 1.60) | 1.27 (1.08, 1.50) |
All cancer death | 2005 | 1405 | 4558 | 372 | 244 | 612 | 1.50 (1.31, 1.72) | 1.37 (1.18, 1.59) |
All cause death | 2005 | 1512 | 4558 | 372 | 293 | 612 | 1.63 (1.44, 1.85) | 1.44 (1.25, 1.65) |
Use in the year before diagnosis | 3584 | 2534 | 5693 | 608 | 431 | 573 | 1.32 (1.19, 1.46) | 1.12 (1.00, 1.26) |
12 month lag | 1360 | 712 | 3733 | 234 | 101 | 464 | 1.35 (1.10, 1.67) | 1.21 (0.96, 1.53) |
Adenocarcinoma | 1813 | 1182 | 4015 | 336 | 186 | 561 | 1.33 (1.14, 1.55) | 1.25 (1.05, 1.49) |
Additional adjusted for smoking and alcoholc | 1091 | 780 | 1469 | 206 | 133 | 204 | 1.30 (1.08, 1.56) | 1.41 (1.13, 1.75) |
Additional adjusted for BMId | 1221 | 825 | 1984 | 234 | 135 | 282 | 1.27 (1.06, 1.53) | 1.26 (1.02, 1.54) |
All loop diureticse | 1984 | 1256 | 4514 | 393 | 211 | 656 | 1.35 (1.17, 1.56) | 1.27 (1.08, 1.50) |
Additionally adjusted for Stagef | 270 | 155 | 409 | 43 | 18 | 66 | 0.88 (0.54, 1.44) | 0.64 (0.35, 1.15) |
Additionally adjusted for Gradeg | 1462 | 945 | 3316 | 258 | 134 | 422 | 1.31 (1.09, 1.57) | 1.26 (1.03, 1.54) |
Restricted to patients with high grade diagnosish | 909 | 610 | 1770 | 137 | 81 | 207 | 1.34 (1.06, 1.69) | 1.37 (1.05, 1.79) |
Restricted to patients surgically treatedi | 1029 | 556 | 3198 | 181 | 85 | 385 | 1.64 (1.30, 2.06) | 1.74 (1.35, 2.23) |
Restricted to any hypertensive medication usej | 899 | 563 | 1914 | 283 | 149 | 434 | 1.31 (1.09, 1.57) | 1.14 (0.93, 1.39) |
Furosemide vs other antihypertensive medicationk | 953 | 593 | 2169 | 372 | 199 | 612 | 1.49 (1.27, 1.76) | 1.31 (1.10, 1.57) |
Year of diagnosisl: 1998 to 2002 | 507 | 365 | 1496 | 116 | 67 | 232 | 1.52 (1.17, 1.98) | 1.50 (1.11, 2.02) |
2003 to 2007 | 719 | 476 | 1779 | 126 | 76 | 211 | 1.60 (1.25, 2.04) | 1.64 (1.24, 2.15) |
2008 to 2013 | 779 | 427 | 1283 | 130 | 56 | 169 | 1.07 (0.81, 1.41) | 1.01 (0.74, 1.38) |
Restricted to any diagnosis of hypertension/edema/MI/HFm | ||||||||
Main analysis | 906 | 541 | 1978 | 264 | 138 | 440 | 1.36 (1.13, 1.64) | 1.18 (0.96, 1.46) |
12 month lag | 615 | 288 | 1606 | 168 | 75 | 334 | 1.46 (1.13, 1.88) | 1.22 (0.91, 1.64) |
Adenocarcinoma | 813 | 502 | 1721 | 235 | 130 | 393 | 1.33 (1.10, 1.62) | 1.16 (0.93, 1.44) |
Additionally adjusted for smoking and alcoholc | 550 | 368 | 739 | 160 | 101 | 155 | 1.36 (1.09, 1.70) | 1.36 (1.04, 1.77) |
Additionally adjusted for BMId | 630 | 401 | 1013 | 177 | 99 | 223 | 1.24 (0.99, 1.55) | 1.14 (0.89, 1.47) |
All loop diureticse | 890 | 533 | 1949 | 280 | 146 | 470 | 1.34 (1.11, 1.61) | 1.18 (0.96, 1.45) |
Additionally adjusted for Stagef | 129 | 68 | 154 | 33 | 51 | 46 | 1.01 (0.58, 1.78) | 0.53 (0.24, 1.15) |
Additionally adjusted for Gradeg | 659 | 408 | 1435 | 174 | 89 | 274 | 1.31 (1.04, 1.65) | 1.11 (0.85, 1.45) |
Year of diagnosisn: 1998 to 2002 | 148 | 108 | 447 | 69 | 35 | 160 | 1.24 (0.85, 1.83) | 0.95 (0.59, 1.54) |
2003 to 2007 | 325 | 208 | 809 | 86 | 56 | 141 | 1.65 (1.22, 2.22) | 1.57 (1.11, 2.23) |
2008 to 2013 | 433 | 225 | 722 | 109 | 47 | 140 | 1.17 (0.85, 1.60) | 1.04 (0.72, 1.49) |